Sundar PichaiSundar Pichai earned $164M in 2023

Catherine Thorpe is the Chief Accounting Officer and interim Principal Financial Officer at Applied Therapeutics since June 2023. With a strong background in accounting, she previously held the position of Managing Director at CFGI, where she led efforts in financial...

Quick Links
A

Catherine Thorpe

Ex-CEO of Applied Therapeutics

Education

Not specified

Field of Expertise

Finance & Banking - Accounting

Sector of Economy

Healthcare

Born

January 1, 1963 - 62 years ago

CEO of Applied Therapeutics for

0 years 9 months (Jun 2023 - Apr 2024)

Previous Experience

Managing Director at CFGI, Stamford Office Managing Partner at CFGI

Rivals

Competitors/colleagues of Catherine Thorpe

Holdings

See how much did Catherine Thorpe make over time.

Catherine Thorpe's holdings reflect her position and confidence in Applied Therapeutics. As of April 2024, she has not personally reported major insider transactions but has been a significant player in driving the company’s financial strategies. Her appointment during a crucial...

Loading...

Insider Trading

See recent insider trades of Catherine Thorpe.

No insider trades found for this CEO.

Compensation History

See how much did Catherine Thorpe make over time.

In 2023, Catherine Thorpe's total compensation at Applied Therapeutics was approximately $9.5 million. This package included a base salary of $630,000, complemented by a one-time bonus of $315,000, reflecting her contributions during a challenging year for the firm. The bulk of her reported income came from equity awards valued at around $8.5 million, solidifying her long-term commitment to the company. This equity component aims to align her interests with those of shareholders as they navigate the path to new drug applications and approvals. Thorpe's compensation is indicative of her strategic role, especially as the company focuses on critically important regulatory milestones. Her fiscal management skills are essential for ensuring the company remains on solid financial footing while pursuing its ambitious drug development goals.

Year

2023

Total Compensation

$9.49M

Salary

$630.00K

Board Justification

We review compensation annually for all employees, including our named executive officers. In setting executive base salaries and bonuses and granting equity incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders and a long-term commitment to our company.

Bonus

$315.00K

Board Justification

The amounts in this column represent the discretionary annual cash bonus paid with respect to the applicable year. For her 2022 performance, Dr. Shendelman received a bonus payable in equal parts cash and RSUs vested in full as of the date of grant. A total of $225,000 of this bonus was payable in cash, 50% of which was paid in January 2023 and 50% of which was paid in June 2023.

Other

$1.08K

Board Justification

The amounts represent matching contributions made by us to the named executive officer’s 401(k) plan account.

Restricted Stock

$8.55M(8.55M RSU)

Board Justification

This column reflects the aggregate grant date fair value of the applicable equity awards granted during the applicable year computed in accordance with ASC 718 for stock-based compensation transactions. Assumptions used in the calculation of these amounts are included in Note 7, 'Stock-Based Compensation' to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023.

Performance Metrics

The performance metrics for the CEO's bonus are based on individual performance, company performance or as otherwise determined appropriate by our compensation committee.